4-(3-(3-(hydroxymethyl)phenyl)imidazo[1,2-b]pyridazin-6-ylamino)cyclohexanol | 1010441-40-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(3-(3-(hydroxymethyl)phenyl)imidazo[1,2-b]pyridazin-6-ylamino)cyclohexanol
• 英文别名: 4-({3-[3-(Hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl}amino)cyclohexan-1-ol；4-[[3-[3-(hydroxymethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]amino]cyclohexan-1-ol
• CAS: 1010441-40-3
• 化学式: C₁₉H₂₂N₄O₂
• mdl: MFCD26392285
• 分子量: 338.409
• InChiKey: QNPGJHXDMBJPMN-UHFFFAOYSA-N

物化性质

• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.368
• 拓扑面积：
  82.7
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE
  申请人：Durand-Reville Thomas

  公开号：US20110021513A1

  公开（公告）日：2011-01-27

  The present invention relates to modulators of IRAK kinase and provides compositions comprising such modulators, as well as methods therewith for treating conditions or diseases mediated by or associated with IRAK kinase.

  本发明涉及IRAK激酶的调节剂，并提供包含这些调节剂的组合物，以及利用这些调节剂治疗由IRAK激酶介导或相关的疾病或病症的方法。
• Diazolodiazine derivatives as kinase inhibitors
  申请人：CELLZOME AG

  公开号：EP1900739A1

  公开（公告）日：2008-03-19

  The invention relates to compounds of formula (I) wherein A1, A2, X and R1 to R5 have the meaning as cited in the description and the claims. Said compounds are useful as Itk protein kinase inhibitors for the treatment or prophylaxis of immunological, inflammatory or allergic disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the production of and use as medicaments.

  本发明涉及式 (I) 的化合物 其中 A1、A2、X 和 R1 至 R5 具有在说明书和权利要求书中引用的含义。所述化合物可作为 Itk 蛋白激酶抑制剂用于治疗或预防免疫性、炎症性或过敏性疾病。本发明还涉及包括上述化合物的药物组合物、此类化合物的制备以及作为药物的生产和使用。
• IRAK MODULATORS FOR TREATING AN INFLAMMATORY CONDITION, CELL PROLIFERATIVE DISORDER, IMMUNE DISORDER
  申请人：Biogen Idec MA Inc.

  公开号：EP2063962A2

  公开（公告）日：2009-06-03
• [EN] DIAZOLODIAZINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE DIAZOLODIAZINE COMME INHIBITEURS DE KINASE
  申请人：CELLZOME UK LTD

  公开号：WO2008025822A1

  公开（公告）日：2008-03-06

  [EN] The invention relates to compounds of formula (I) wherein A¹, A², X and R¹ to R⁵ have the meaning as cited in the description and the claims. Said compounds are useful as Itk protein kinase inhibitors for the treatment or prophylaxis o f immunological, inflammatory or allergic disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the production of and use as medicaments.
  [FR] L'invention concerne des composés de formule (I) dans laquelle A¹, A², X et R¹ à R⁵ sont tels que définis dans le descriptif et les revendications. Lesdits composés sont utilisés comme inhibiteurs de la protéine kinase Itk pour le traitement ou la prophylaxie de troubles immunologiques, inflammatoires ou allergiques. L'invention concerne également des compositions pharmaceutiques renfermant ces composés, la préparation de ces composés ainsi que leur production et leur utilisation en tant que médicaments.
• [EN] MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE<br/>[FR] MODULATEURS DE LA KINASE ASSOCIÉE AU RÉCEPTEUR DE L'INTERLEUKINE-1
  申请人：BIOGEN IDEC INC

  公开号：WO2008030579A2

  公开（公告）日：2008-03-13

  [EN] The present invention relates to modulators of IRAK kinase and provides compositions comprising such modulators, as well as methods therewith for treating conditions or diseases mediated by or associated with IRAK kinase.
  [FR] La présente invention concerne des modulateurs de la kinase IRAK (Interleukin-1 Receptor-Associated Kinase) et des compositions comprenant de tels modulateurs, ainsi que des procédés permettant de traiter des affections ou des maladies induites par la kinase IRAK ou associées à la kinase IRAK.